Taysha Gene Therapies, Inc. Operating Lease Liability
Taysha Gene Therapies, Inc. (TSHA) had Operating Lease Liability of $7.29 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities
us-gaap:OperatingLeaseLiability · last filed 2026-08-11
- 2026-06-30: Operating Lease, Liability $7.29M.
- 2026-03-31: Operating Lease, Liability $19.32M.
- 2025-12-31: Operating Lease, Liability $19.66M.
- 2025-09-30: Operating Lease, Liability $17.75M.
| Period end | Operating Lease, Liability |
|---|---|
| 2026-06-30 | $7.29M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $19.32M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $19.66M 10-K · filed 2026-03-19 |
| 2025-09-30 | $17.75M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $18.13M 10-Q · filed 2025-08-12 |
| 2025-03-31 | $18.50M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $18.85M 10-K · filed 2025-02-26 |
| 2024-09-30 | $19.18M 10-Q · filed 2024-11-13 |
| 2024-06-30 | $19.52M 10-Q · filed 2024-08-12 |
| 2024-03-31 | $19.83M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $20.25M 10-K · filed 2024-03-19 |
| 2023-09-30 | $20.29M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $20.83M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $21.35M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $21.64M 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |